Topic: regulatory review future implications

Moderna's mRNA Flu Vaccine Outperforms Traditional Shot in Trial

Moderna's mRNA flu vaccine showed 27% better protection than traditional flu shots in a phase 3 trial with 41,000 participants, especially benefiting adults over 65. The mRNA technology allows faster adaptation to flu strains and potential for combination vaccines, addressing influenza's rapid mu...